Bulletin of the Korean Chemical Society

Korean Chemical Society (대한화학회)
권호 표지
DOI QR코드

DOI QR Code

Polymorphic Characterization of Pharmaceutical Solids, Donepezil Hydrochloride, by 13C CP/MAS Solid-State Nuclear Magnetic Resonance Spectroscopy

  • Park, Tae-Joon (Dept. of Chemistry and Protein Res. Cener for Bio-Industry, Hankuk University of Foreign Studies) ;
  • Ko, Dong-Hyun (CJ Cheil Jedang Corp. Pharmarceutical Research Institute) ;
  • Kim, Young-Ju (CJ Cheil Jedang Corp. Pharmarceutical Research Institute) ;
  • Kim, Yon-Gae (Dept. of Chemistry and Protein Res. Cener for Bio-Industry, Hankuk University of Foreign Studies)
  • Published : 2009.09.20
Download PDF
⟨ Previous Next ⟩

Abstract

Donepezil hydrochloride is a reversible acetylcholinesterase inhibitor that is used in the treatment of Alzheimer’s disease to improve the cognitive performance. It shows different crystalline forms including hydrates. Therefore, it is very important to confirm the polymorphic forms in the formulations of pharmaceutical materials because polymorphs of the same drug often exhibit significant differences in solubility, bioavailability, processability and physical/chemical stability. In this paper, four different forms of donepezil hydrochloride were prepared and characterized using X-ray powder diffraction, Fourier transform infrared, and solid-state nuclear magnetic resonance (NMR) spectroscopy. This study showed that solid-state NMR spectroscopy is a powerful technique for obtaining structural information and the polymorphology of pharmaceutical solids.

Keywords

References

  1. Byrn, S.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikian, G. Pharm. Res. 1995, 12, 945 https://doi.org/10.1023/A:1016241927429
  2. Saindon, P. J.; Cauchon, N. S.; Sutton, P. A.; Chang, C. J.; Peck, G. E.; Byrn, S. R. Pahrm. Res. 1993, 10, 197 https://doi.org/10.1023/A:1018922407786
  3. Geppi, M.; Mollica, G.; Borsacchi, S.; Veracini, C. A. Applied Spectroscopy Reviews 2008, 43, 202 https://doi.org/10.1080/05704920801944338
  4. Kim, Y. A.; Kim, A. R. Bull. Korean Chem. Soc. 2002, 23, 1729 https://doi.org/10.5012/bkcs.2002.23.12.1729
  5. Katsuhiko, M.; Sachio, T.; Hiroyuki, K.; Yasuyuki, S.; Tetsuo, H.; Etsuo, Y.; Katsuhide, T. Int. J. Pharm. 2006, 318, 146 https://doi.org/10.1016/j.ijpharm.2006.03.029
  6. Park, J. S.; Kang, H. W.; Park, S. J.; Kim, C. K. Eur. J. Pharm. Biopharm. 2005, 60, 407 https://doi.org/10.1016/j.ejpb.2005.01.010
  7. Lubach, J. W; Padden, B. E.; Winslow, S. L.; Salsbury, J. S.; Masters, D. B.; Topp, E. M.; Munson, E. J. Anal. Bioanal. Chem. 2004, 378, 1504 https://doi.org/10.1007/s00216-003-2381-4
  8. Haleblian, J.; McCrone, W. J. Pharm. Sci. 1969, 58, 911 https://doi.org/10.1002/jps.2600580802
  9. Fukuoka, E.; Makita, M.; Yamamura, S. Chem. Pharm. Bull. 1986, 34, 4314 https://doi.org/10.1248/cpb.34.4314
  10. Law, S. L.; Lo, W. Y.; Lin, F. M.; Chaing, C. H. Int. J. Pharm. 1992, 84, 161 https://doi.org/10.1016/0378-5173(92)90056-8
  11. Fukuoka, E.; Makita, M.; Yamamura, S. Chem. Pharm. Bull. 1989, 37, 1047 https://doi.org/10.1248/cpb.37.1047
  12. Monkhouse, D. C.; Van, C. L. Drug. Dev. Indust. Pharm. 1984, 10, 1175 https://doi.org/10.3109/03639048409039054
  13. Bugay, D. E. Pharm. Res. 1993, 10, 317 https://doi.org/10.1023/A:1018967717781
  14. Brittain, H. G. J. Pharm. Sci. 1997, 86, 405 https://doi.org/10.1021/js960238e
  15. Shintani, E. Y.; Uchida, K. M. Am. J. Health-Syst. Pharm. 1997, 54, 2805
  16. Rho, J. P.; Lipson, L. G. Formulary 1997, 32, 677
  17. Bryson, H. M.; Benfield, P. Drugs & Aging 1997, 19, 234
  18. Elati, C. R.; Vankawala, P. J. Indian J. Chem. 2005, 44B, 1231
  19. Vrbinc, M.; Jordan-Kotar, B.; Smrkolj, M.; Vrecer, F. Acta Chim. Slov. 2007, 54, 254
  20. Hartmann, S. R.; Hahn, E. L. Phys. Rev. 1962, 128, 2043
  21. Dixon, W. T.; Schaefer, J.; Sefcik, M. D.; Stejskal, E. O.; McKay, R. A. J. Magn. Reson. 1982, 49, 341
  22. Park, T. J.; Kim, J.; Kim, T. K.; Park, H. M.; Choi, S. S.; Kim, Y. Bull. Kor. Chem. Soc. 2008, 29, 2459 https://doi.org/10.5012/bkcs.2008.29.12.2459
  23. Park, T. J.; Choi, S. S.; Kim, Y. Bull. Kor. Chem. Soc. 2009, 30, 149 https://doi.org/10.5012/bkcs.2009.30.1.149
  24. Bennett, A. E.; Rienstra, C. M.; Auger, M.; Lakshmi, K. V.; Griffin, R. G. J. Chem. Phys. 1995, 103, 6951 https://doi.org/10.1063/1.470372

Cited by

  1. Characterization of Oral Disintegrating Film Containing Donepezil for Alzheimer Disease vol.13, pp.1, 2012, https://doi.org/10.1208/s12249-011-9729-4
  2. Solution-Mediated Phase Transformation of a Hydrate to its Anhydrous Form of Donepezil Hydrochloride vol.36, pp.8, 2013, https://doi.org/10.1002/ceat.201300131
  3. Determination of the Solubility, Dissolution Enthalpy and Entropy of Donepezil Hydrochloride Polymorphic Form III in Different Solvents vol.42, pp.4, 2013, https://doi.org/10.1007/s10953-013-9986-9
  4. Cl solid-state NMR of HCl salts of active pharmaceutical ingredients: structural prediction, spectral fingerprinting and polymorph recognition vol.16, pp.31, 2014, https://doi.org/10.1039/C4CE00544A
  5. Spectroscopic Techniques for Nondestructive Quality Inspection of Pharmaceutical Products: A Review vol.40, pp.4, 2015, https://doi.org/10.5307/JBE.2015.40.4.394
  6. Evaluation of solid-state thermal stability of donepezil in binary mixtures with excipients using instrumental techniques vol.130, pp.1, 2017, https://doi.org/10.1007/s10973-017-6250-3
  7. Effect of polymer, plasticizer and filler on orally disintegrating film vol.40, pp.1, 2009, https://doi.org/10.3109/03639045.2012.749889